In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
BUSINESS
Takeda’s Operating Profit Dips by More than Half in FY2023
Takeda Pharmaceutical’s operating profit slumped by more than half in FY2023 ended March 2024, marred by major patent expiries and impairment charges following failed trials. CEO Christophe Weber summed up the year as “well-managed but tough.” According to its earnings…
To read the full story
Related Article
- Takeda’s April-December Sales Up 4.6%, but Flat at CER
February 2, 2024
- Takeda’s H1 Profit Tumbles on Write-Down Tied to Trial Setbacks, Outlook Slashed
October 27, 2023
- Takeda Q1 Sales Up 8.9%, Led by Key Product Growth and Weak Yen
July 28, 2023
- Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
May 12, 2023
- Takeda Logs Double-Digit Growth, Led by Core Products and Weaker Yen
February 3, 2023
- Takeda’s H1 Sales Up 10% Backed by Robust Mainstays, Hefty FX Gains
October 28, 2022
- Takeda’s Q1 Sales Up 2.4% Despite Diabetes Divesture Last Year, Gets Hefty FX Gains
July 29, 2022
- Takeda Poised to Weather LOEs in Next 2 Years with 10 Growth Drivers: CEO
May 12, 2022
- Takeda’s FY2021 Sales Up 11.6%; Weak Yen Tailwind for Revenue, but Drags Profits
May 12, 2022
- Takeda Delivers Growth in All Focus Therapeutic Areas in April-December
February 4, 2022
- Takeda’s H1 Sales Log Two-Digit Growth Driven by Global Brands, FDA Wraps Up Plant Re-Inspection
October 29, 2021
- Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
August 2, 2021
BUSINESS
- Axcelead DDP, Lilly Ink Research Collaboration Pact
September 6, 2024
- JN.1-Targeting Nuvaxovid Approved in Japan: Takeda
September 6, 2024
- Keytruda Nabs Best-Seller Drug Title for 11th Straight Month: Encise
September 6, 2024
- Organon’s OG-8276A for Dysmenorrhea Hits Goal in Japan PIII Study
September 5, 2024
- Daiichi Sankyo Wins Japan Approval for Updated COVID Jab for JN.1
September 5, 2024
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…